SCHEMBL2476949

SCHEMBL2476949

CC(C)N1CCN(c2ccc(Nc3cc(NCc4cc(F)cc(F)c4)c(C(N)=O)cn3)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 11/20 0.56
JAK3 P52333 8/20 0.52
IRAK4 Q9NWZ3 4/20 0.52
JAK2 O60674 2/20 0.52
JAK1 P23458 2/20 0.52
TYK2 P29597 2/20 0.52
SYK P43405 1/20 0.44
CSF1R P07333 1/20 0.43
BTK Q06187 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477813 0.97 STAT6 (0.53) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL2483540 0.91 JAK3 (0.52) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL12301519 0.90 STAT6 (0.55) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL2478337 0.90 JAK3 (0.67) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL2508033 0.88 STAT6 (0.53) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL12301690 0.88 STAT6 (0.60) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL2481818 0.88 STAT6 (0.72) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL2485695 0.87 JAK3 (0.58) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL12301564 0.87 STAT6 (0.55) STAT6JAK3IRAK4JAK2JAK1
SCHEMBL2482474 0.87 STAT6 (0.55) STAT6JAK3IRAK4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US claimed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP claimed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US claimed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA STAT6 8/4885JAK3 1/4885IRAK4 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.